President Trump issued an executive order to limit the amount Medicare pays for Part B and Part D prescription drugs and biologics to the “most-favored-nation” price but it is uncertain what an implementing rule would consist of and when the model payment plans would be implemented.
What seems clear from the administration’s many drug pricing announcements is that the president hopes to make antagonism of biopharma companies part of his reelection strategy, an approach that could spell trouble for industry regardless of who wins in November. (See sidebar.) In July, Trump announced that he would be issuing four executive orders on drug pricing, including a directive to advance international reference pricing for lowering Medicare Part B drug costs unless industry offered an alternative solution in the next 30 days